Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Corneal Transplantation | 13 | 2024 | 315 | 3.660 |
Why?
|
Dry Eye Syndromes | 17 | 2022 | 384 | 3.160 |
Why?
|
Corneal Diseases | 10 | 2024 | 535 | 2.190 |
Why?
|
Cornea | 19 | 2024 | 1316 | 1.560 |
Why?
|
Corneal Dystrophies, Hereditary | 3 | 2022 | 62 | 1.050 |
Why?
|
Keratitis | 4 | 2022 | 239 | 0.970 |
Why?
|
Keratoplasty, Penetrating | 6 | 2024 | 143 | 0.970 |
Why?
|
Glaucoma, Angle-Closure | 2 | 2017 | 192 | 0.930 |
Why?
|
Corneal Neovascularization | 3 | 2022 | 184 | 0.910 |
Why?
|
Trigeminal Nerve Diseases | 2 | 2022 | 47 | 0.890 |
Why?
|
Corneal Opacity | 2 | 2024 | 52 | 0.850 |
Why?
|
Tears | 6 | 2022 | 254 | 0.830 |
Why?
|
Cataract | 3 | 2022 | 837 | 0.830 |
Why?
|
Cataract Extraction | 2 | 2017 | 464 | 0.790 |
Why?
|
Corneal Perforation | 4 | 2022 | 28 | 0.730 |
Why?
|
Keratoconus | 1 | 2022 | 112 | 0.720 |
Why?
|
Graft vs Host Disease | 9 | 2024 | 3078 | 0.680 |
Why?
|
Epithelium, Corneal | 2 | 2020 | 246 | 0.670 |
Why?
|
Graft Survival | 7 | 2024 | 3890 | 0.660 |
Why?
|
Angiogenesis Inhibitors | 3 | 2022 | 2046 | 0.650 |
Why?
|
alpha-MSH | 3 | 2024 | 71 | 0.650 |
Why?
|
Vascular Endothelial Growth Factor A | 4 | 2022 | 3504 | 0.630 |
Why?
|
Optics and Photonics | 1 | 2019 | 305 | 0.570 |
Why?
|
Intravitreal Injections | 1 | 2019 | 391 | 0.560 |
Why?
|
Chemotaxis, Leukocyte | 3 | 2016 | 657 | 0.550 |
Why?
|
Corneal Ulcer | 3 | 2023 | 125 | 0.540 |
Why?
|
Diagnostic Techniques, Ophthalmological | 1 | 2019 | 251 | 0.540 |
Why?
|
Th17 Cells | 4 | 2020 | 786 | 0.540 |
Why?
|
Eye | 3 | 2020 | 710 | 0.540 |
Why?
|
Corneal Surgery, Laser | 1 | 2016 | 9 | 0.520 |
Why?
|
Visual Acuity | 8 | 2024 | 2672 | 0.510 |
Why?
|
Keratomileusis, Laser In Situ | 1 | 2016 | 81 | 0.470 |
Why?
|
Intraocular Pressure | 3 | 2017 | 1304 | 0.450 |
Why?
|
E-Selectin | 1 | 2016 | 576 | 0.440 |
Why?
|
Mice, Inbred BALB C | 13 | 2024 | 6219 | 0.430 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 890 | 0.420 |
Why?
|
Chemokine CCL20 | 1 | 2013 | 64 | 0.420 |
Why?
|
Receptors, CCR6 | 1 | 2013 | 73 | 0.420 |
Why?
|
Corneal Edema | 2 | 2023 | 45 | 0.420 |
Why?
|
Myeloid Cells | 1 | 2017 | 839 | 0.380 |
Why?
|
Endothelium, Corneal | 4 | 2024 | 212 | 0.380 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 658 | 0.380 |
Why?
|
Graft Rejection | 4 | 2024 | 4498 | 0.380 |
Why?
|
Keratitis, Herpetic | 2 | 2022 | 76 | 0.370 |
Why?
|
Descemet Stripping Endothelial Keratoplasty | 2 | 2022 | 110 | 0.350 |
Why?
|
Retinal Diseases | 1 | 2016 | 702 | 0.340 |
Why?
|
Conjunctiva | 7 | 2022 | 477 | 0.340 |
Why?
|
Conjunctivitis | 2 | 2021 | 153 | 0.340 |
Why?
|
Hyperemia | 2 | 2021 | 224 | 0.330 |
Why?
|
Disease Models, Animal | 14 | 2024 | 18289 | 0.330 |
Why?
|
Artificial Organs | 3 | 2016 | 149 | 0.320 |
Why?
|
Mice, Inbred C57BL | 17 | 2024 | 22321 | 0.300 |
Why?
|
Eye Diseases | 3 | 2024 | 659 | 0.300 |
Why?
|
Antibodies, Neutralizing | 4 | 2024 | 2010 | 0.290 |
Why?
|
Osmolar Concentration | 2 | 2019 | 655 | 0.270 |
Why?
|
Receptors, CCR7 | 3 | 2016 | 104 | 0.270 |
Why?
|
Postoperative Complications | 3 | 2024 | 15749 | 0.260 |
Why?
|
Recombinant Fusion Proteins | 1 | 2015 | 3737 | 0.260 |
Why?
|
Retina | 2 | 2016 | 2648 | 0.260 |
Why?
|
Cell Movement | 3 | 2017 | 5192 | 0.260 |
Why?
|
Lacrimal Apparatus | 2 | 2020 | 224 | 0.250 |
Why?
|
T-Lymphocytes, Regulatory | 4 | 2024 | 3110 | 0.240 |
Why?
|
Chemokine CCL21 | 2 | 2016 | 49 | 0.240 |
Why?
|
Anti-Allergic Agents | 2 | 2018 | 153 | 0.240 |
Why?
|
Vascular Endothelial Growth Factor Receptor-3 | 2 | 2015 | 117 | 0.230 |
Why?
|
Melanocortins | 1 | 2024 | 10 | 0.230 |
Why?
|
Mustard Gas | 1 | 2023 | 9 | 0.220 |
Why?
|
Receptors, Neurokinin-1 | 2 | 2022 | 133 | 0.210 |
Why?
|
Flow Cytometry | 9 | 2017 | 5879 | 0.210 |
Why?
|
Pemphigoid, Benign Mucous Membrane | 1 | 2023 | 113 | 0.210 |
Why?
|
Burns, Chemical | 1 | 2023 | 123 | 0.200 |
Why?
|
Fuchs' Endothelial Dystrophy | 1 | 2024 | 103 | 0.200 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2024 | 4405 | 0.200 |
Why?
|
Animals | 30 | 2024 | 168731 | 0.190 |
Why?
|
Academies and Institutes | 1 | 2024 | 326 | 0.190 |
Why?
|
Mice | 22 | 2024 | 81792 | 0.180 |
Why?
|
Vascular Endothelial Growth Factor C | 3 | 2017 | 124 | 0.180 |
Why?
|
Eye Infections, Viral | 1 | 2021 | 60 | 0.180 |
Why?
|
Blast Injuries | 1 | 2024 | 318 | 0.170 |
Why?
|
Optic Nerve | 1 | 2023 | 568 | 0.170 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2017 | 3805 | 0.170 |
Why?
|
Limbus Corneae | 1 | 2021 | 144 | 0.170 |
Why?
|
Th1 Cells | 2 | 2015 | 1039 | 0.170 |
Why?
|
T-Lymphocytes | 2 | 2021 | 10262 | 0.160 |
Why?
|
Interferon-gamma | 3 | 2024 | 3159 | 0.160 |
Why?
|
Hematopoietic Stem Cell Transplantation | 5 | 2024 | 5753 | 0.160 |
Why?
|
Tissue Adhesives | 1 | 2020 | 177 | 0.150 |
Why?
|
Registries | 2 | 2024 | 8293 | 0.150 |
Why?
|
Ophthalmic Nerve | 2 | 2015 | 43 | 0.150 |
Why?
|
Ophthalmology | 1 | 2024 | 560 | 0.140 |
Why?
|
Thrombospondin 1 | 1 | 2019 | 256 | 0.140 |
Why?
|
Prostheses and Implants | 2 | 2014 | 1273 | 0.140 |
Why?
|
Axons | 2 | 2023 | 1678 | 0.140 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 2023 | 1118 | 0.140 |
Why?
|
Lymphangiogenesis | 2 | 2015 | 171 | 0.140 |
Why?
|
Chemokine CCL19 | 1 | 2016 | 37 | 0.130 |
Why?
|
Posterior Eye Segment | 1 | 2016 | 18 | 0.130 |
Why?
|
Matrix Metalloproteinase 9 | 2 | 2016 | 636 | 0.130 |
Why?
|
Humans | 38 | 2024 | 765734 | 0.130 |
Why?
|
Dendritic Cells | 3 | 2016 | 2746 | 0.120 |
Why?
|
Conjunctival Diseases | 1 | 2016 | 109 | 0.120 |
Why?
|
Corneal Endothelial Cell Loss | 1 | 2015 | 24 | 0.120 |
Why?
|
Phacoemulsification | 1 | 2017 | 151 | 0.120 |
Why?
|
Keratoconjunctivitis Sicca | 1 | 2014 | 26 | 0.120 |
Why?
|
Lens Implantation, Intraocular | 1 | 2017 | 192 | 0.120 |
Why?
|
Tobramycin | 1 | 2014 | 65 | 0.120 |
Why?
|
Military Personnel | 1 | 2024 | 1252 | 0.120 |
Why?
|
Methylprednisolone | 1 | 2016 | 386 | 0.120 |
Why?
|
DNA Damage | 1 | 2024 | 2461 | 0.110 |
Why?
|
Aqueous Humor | 1 | 2014 | 152 | 0.110 |
Why?
|
Wound Healing | 2 | 2023 | 2790 | 0.110 |
Why?
|
P-Selectin | 1 | 2016 | 597 | 0.110 |
Why?
|
Autistic Disorder | 1 | 2023 | 1239 | 0.110 |
Why?
|
Oxidative Stress | 1 | 2024 | 3140 | 0.100 |
Why?
|
Scopolamine | 1 | 2013 | 92 | 0.100 |
Why?
|
Immunosuppressive Agents | 2 | 2016 | 4207 | 0.100 |
Why?
|
Androstadienes | 1 | 2014 | 347 | 0.100 |
Why?
|
Cell Proliferation | 3 | 2017 | 10428 | 0.100 |
Why?
|
Optic Nerve Diseases | 1 | 2016 | 342 | 0.100 |
Why?
|
Fluorophotometry | 3 | 2018 | 40 | 0.100 |
Why?
|
Tacrolimus | 1 | 2016 | 752 | 0.100 |
Why?
|
Lymphoid Tissue | 1 | 2013 | 444 | 0.100 |
Why?
|
Phosphodiesterase 4 Inhibitors | 1 | 2012 | 37 | 0.100 |
Why?
|
Interleukin-7 | 1 | 2012 | 147 | 0.100 |
Why?
|
Major Histocompatibility Complex | 1 | 2014 | 879 | 0.090 |
Why?
|
Nerve Degeneration | 1 | 2016 | 748 | 0.090 |
Why?
|
Bioprosthesis | 1 | 2016 | 589 | 0.090 |
Why?
|
Extracellular Matrix | 1 | 2019 | 1727 | 0.090 |
Why?
|
Microscopy, Confocal | 4 | 2023 | 1965 | 0.090 |
Why?
|
Ophthalmic Solutions | 3 | 2021 | 312 | 0.090 |
Why?
|
Immune Tolerance | 2 | 2024 | 2324 | 0.090 |
Why?
|
Retrospective Studies | 10 | 2024 | 81457 | 0.090 |
Why?
|
Male | 26 | 2024 | 363585 | 0.080 |
Why?
|
Fluorescein | 2 | 2022 | 175 | 0.080 |
Why?
|
Transplantation, Homologous | 5 | 2017 | 4858 | 0.080 |
Why?
|
Lymph Nodes | 3 | 2016 | 3451 | 0.080 |
Why?
|
Time Factors | 5 | 2021 | 40066 | 0.080 |
Why?
|
Mice, Inbred C3H | 2 | 2024 | 914 | 0.080 |
Why?
|
Mesenchymal Stem Cell Transplantation | 1 | 2014 | 504 | 0.080 |
Why?
|
RNA | 3 | 2016 | 2717 | 0.080 |
Why?
|
Interleukin-2 | 1 | 2016 | 1896 | 0.080 |
Why?
|
Ligands | 1 | 2016 | 3273 | 0.080 |
Why?
|
Female | 22 | 2024 | 395961 | 0.080 |
Why?
|
Glucocorticoids | 1 | 2018 | 2132 | 0.080 |
Why?
|
Models, Animal | 1 | 2015 | 2120 | 0.080 |
Why?
|
Autoimmune Diseases | 1 | 2020 | 2223 | 0.070 |
Why?
|
Gene Expression Regulation | 3 | 2016 | 11888 | 0.070 |
Why?
|
Neovascularization, Physiologic | 1 | 2015 | 1377 | 0.070 |
Why?
|
Inflammation Mediators | 1 | 2016 | 1885 | 0.070 |
Why?
|
Macrophages | 2 | 2023 | 5772 | 0.070 |
Why?
|
Neovascularization, Pathologic | 1 | 2017 | 2630 | 0.070 |
Why?
|
Transplantation, Isogeneic | 2 | 2017 | 251 | 0.070 |
Why?
|
Anti-Inflammatory Agents | 1 | 2016 | 1807 | 0.070 |
Why?
|
Antigen-Presenting Cells | 2 | 2023 | 962 | 0.060 |
Why?
|
Lymphocyte Activation | 1 | 2016 | 5501 | 0.060 |
Why?
|
Disease Management | 1 | 2016 | 2534 | 0.060 |
Why?
|
Endothelial Cells | 3 | 2023 | 3584 | 0.060 |
Why?
|
Receptors, Melanocortin | 1 | 2024 | 23 | 0.060 |
Why?
|
Signal Transduction | 3 | 2017 | 23589 | 0.060 |
Why?
|
Cell Line | 3 | 2024 | 15542 | 0.060 |
Why?
|
Mechlorethamine | 1 | 2023 | 129 | 0.050 |
Why?
|
Mesenchymal Stem Cells | 1 | 2014 | 1663 | 0.050 |
Why?
|
Middle Aged | 12 | 2024 | 222903 | 0.050 |
Why?
|
Prospective Studies | 4 | 2022 | 54795 | 0.050 |
Why?
|
Tumor Necrosis Factor-alpha | 3 | 2023 | 4352 | 0.050 |
Why?
|
Streptozocin | 1 | 2023 | 189 | 0.050 |
Why?
|
Tissue Preservation | 1 | 2023 | 169 | 0.050 |
Why?
|
Cytoprotection | 1 | 2023 | 200 | 0.050 |
Why?
|
Eye Pain | 1 | 2022 | 46 | 0.050 |
Why?
|
Descemet Membrane | 1 | 2022 | 70 | 0.050 |
Why?
|
Coculture Techniques | 2 | 2017 | 1336 | 0.050 |
Why?
|
Substance P | 1 | 2022 | 331 | 0.050 |
Why?
|
Neutrophil Infiltration | 1 | 2023 | 394 | 0.040 |
Why?
|
Hydrogen Peroxide | 1 | 2024 | 743 | 0.040 |
Why?
|
Chronic Disease | 3 | 2021 | 9351 | 0.040 |
Why?
|
Cyanoacrylates | 1 | 2020 | 47 | 0.040 |
Why?
|
Immunoglobulin A | 1 | 2023 | 992 | 0.040 |
Why?
|
Prevalence | 3 | 2022 | 15833 | 0.040 |
Why?
|
Immunity, Innate | 1 | 2012 | 3078 | 0.040 |
Why?
|
Aged | 9 | 2024 | 171050 | 0.040 |
Why?
|
Interleukin-1beta | 2 | 2016 | 1027 | 0.040 |
Why?
|
Aged, 80 and over | 5 | 2024 | 59459 | 0.040 |
Why?
|
Ultraviolet Rays | 1 | 2024 | 1099 | 0.040 |
Why?
|
Risk Factors | 4 | 2021 | 74831 | 0.040 |
Why?
|
Cytokines | 3 | 2020 | 7424 | 0.040 |
Why?
|
Cell Death | 1 | 2024 | 1678 | 0.040 |
Why?
|
Inflammation | 3 | 2024 | 10846 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2015 | 9245 | 0.040 |
Why?
|
Double-Blind Method | 3 | 2018 | 12433 | 0.040 |
Why?
|
Environment | 1 | 2024 | 1115 | 0.040 |
Why?
|
Adolescent | 5 | 2024 | 88781 | 0.040 |
Why?
|
Prosthesis Design | 2 | 2014 | 2105 | 0.040 |
Why?
|
Rabbits | 1 | 2023 | 4733 | 0.030 |
Why?
|
Child, Preschool | 3 | 2024 | 42468 | 0.030 |
Why?
|
Gene Expression | 2 | 2022 | 7584 | 0.030 |
Why?
|
Vision Disorders | 1 | 2023 | 1087 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2014 | 7477 | 0.030 |
Why?
|
Immunohistochemistry | 3 | 2014 | 11007 | 0.030 |
Why?
|
Morbidity | 1 | 2021 | 1749 | 0.030 |
Why?
|
Cells, Cultured | 3 | 2016 | 18972 | 0.030 |
Why?
|
Meibomian Glands | 1 | 2014 | 74 | 0.030 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2016 | 305 | 0.030 |
Why?
|
Young Adult | 4 | 2024 | 59852 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor D | 1 | 2014 | 61 | 0.030 |
Why?
|
Miniaturization | 1 | 2014 | 150 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2017 | 548 | 0.030 |
Why?
|
Eye Burns | 1 | 2014 | 64 | 0.030 |
Why?
|
Administration, Topical | 1 | 2016 | 703 | 0.030 |
Why?
|
Monocytes | 1 | 2023 | 2594 | 0.030 |
Why?
|
Lymphocyte Culture Test, Mixed | 1 | 2014 | 511 | 0.030 |
Why?
|
Staining and Labeling | 1 | 2018 | 1070 | 0.030 |
Why?
|
Glaucoma | 1 | 2023 | 1194 | 0.030 |
Why?
|
Adult | 7 | 2024 | 222974 | 0.030 |
Why?
|
Adoptive Transfer | 1 | 2016 | 827 | 0.030 |
Why?
|
Corneal Stroma | 1 | 2014 | 166 | 0.030 |
Why?
|
Eyelid Diseases | 1 | 2014 | 155 | 0.030 |
Why?
|
Treatment Outcome | 4 | 2024 | 65180 | 0.030 |
Why?
|
Infant | 2 | 2024 | 36363 | 0.020 |
Why?
|
Isoantigens | 1 | 2014 | 562 | 0.020 |
Why?
|
United States | 3 | 2024 | 72898 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2023 | 4527 | 0.020 |
Why?
|
Child | 3 | 2024 | 80499 | 0.020 |
Why?
|
Cyclohexanecarboxylic Acids | 1 | 2012 | 139 | 0.020 |
Why?
|
Cell Count | 1 | 2015 | 1823 | 0.020 |
Why?
|
RNA, Messenger | 2 | 2016 | 12769 | 0.020 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2014 | 975 | 0.020 |
Why?
|
Membrane Transport Proteins | 1 | 2014 | 1029 | 0.020 |
Why?
|
Forkhead Transcription Factors | 1 | 2016 | 1624 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8876 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2016 | 4850 | 0.020 |
Why?
|
Apoptosis | 1 | 2023 | 9511 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2014 | 2626 | 0.020 |
Why?
|
Nitriles | 1 | 2012 | 982 | 0.020 |
Why?
|
Glycoproteins | 1 | 2014 | 2194 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2021 | 39180 | 0.020 |
Why?
|
Autoimmunity | 1 | 2014 | 1354 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2017 | 2242 | 0.020 |
Why?
|
Incidence | 1 | 2024 | 21478 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2014 | 6307 | 0.010 |
Why?
|
Patient Selection | 1 | 2017 | 4254 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2017 | 3478 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2024 | 26332 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2017 | 5526 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2020 | 11641 | 0.010 |
Why?
|
Pregnancy | 1 | 2023 | 30248 | 0.010 |
Why?
|
Quality of Life | 1 | 2021 | 13462 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 7424 | 0.010 |
Why?
|
Disease Progression | 1 | 2012 | 13614 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2015 | 26284 | 0.010 |
Why?
|